Resistance to chemotherapy is a significant barrier to the effective management of prostate cancer. Human pregnane X receptor (hPXR), an orphan nuclear receptor known for its activation by many important clinical drugs, interacts with many cellular signaling pathways during carcinogenesis and is a major transcription factor regulating the expression of drug metabolism enzymes, including transporters.
Introduction
Cancer is a major public health problem in the United States, accounting for one in four deaths (1) . Chemotherapy is one of the three most common treatment modalities of cancer, but its efficacy is limited by the resistance of cancer cells to drugs. Induction of drug metabolizing enzymes (DME) and efflux transporters has been regarded as one of major mechanisms of chemoresistance (2, 3) . The differential inductions or activities of DMEs may account for the variations of drug efficacy, but the precise mechanism of inductions remains unknown.
Pregnane X receptor (PXR; also called PAR, SXR, or NR1I2) is a nuclear receptor that has been identified as a master regulator of DMEs (4, 5) . Upon activation with ligands, PXR translocates from cytosol into nucleus and regulates transcription of its target genes (6) . The significance of PXR in drug metabolism and disposition is implicated by its activation by a variety of structurally diverse compounds (7) and by its role in regulating the transcriptions of many important DMEs (6, (8) (9) (10) (11) (12) . Two most important DME families, cytochrome P450 3A (CYP3A) and ATP-binding cassette (ABC) transporters, are predominantly regulated by PXR. The induction of ABC transporters, including P-glycoprotein, has been known to cause multidrug resistance of cancer (13) . CYP3A4 accounts for the oxidative metabolism of >60% of clinical drugs, including many chemotherapeutics (14) . Recently, it has been shown that disruption of PXR activation is a mechanism involved for ketoconazole to inhibit the induction of DMEs, including CYP3A4 and multidrug resistance 1 (MDR1; ref. 15) .
PXR is mainly expressed in liver, colon, and intestinal tissues (8) . Although many researches have explored the characteristics and functions of PXR in normal absorption and metabolism system, little work has been done to evaluate its role in cancerous tissues. PXR expression has been detected in breast (16, 17) and endometrial cancers (18) . The importance of PXR in cancer is underlined by the studies demonstrating the activation of human PXR by some commonly used chemotherapeutic agents (19) (20) (21) . However, there are few studies being done or reported to examine a possible role of PXR in cancerous tissues in resistance to chemotherapy.
The present study is undertaken to test the hypothesis that PXR in cancerous tissues is a determinant of tumor responses toward chemotherapy. Here, we report that PXR expression was detected in prostate cell lines and tissues. Preactivation of PXR with SR12813 led to an enhanced resistance to chemotherapeutics. Downregulation of PXR in prostate cancer cells resulted in sensitization toward chemotherapeutic agents. Our studies suggest an important role for PXR in determining the responses of tumor cells toward chemotherapy.
Materials and Methods
Materials. The human prostate cancer cell line PC-3, DU145, and LNCap cells were obtained from American Type Culture Collection. Human prostate normal or cancerous tissue array was obtained from Biomax. All cell culture, reverse transcription (RT) and immunochemistry reagents were purchased from Invitrogen unless otherwise indicated. Fetal bovine serum (FBS) and puromycin were purchased from Sigma. Declere was supplied by Cell Marque Corporation. Anti-PXR purified rabbit antibody was available from Biolegend. PXR (H-1) mouse monoclonal antibody was from Santa Cruz Biotechnology, Inc. CYP3A4 primary antibody was from Calbiochem. SR12813 (dissolved in DMSO), Taxol (dissolved in DMSO), and vinblastine (dissolved in water) were acquired from BIOMOL International L.P. The regular PCR reagents, MTS solution, luciferase assay system, pGL3 vector, and cell culture lysis reagent were from Promega. All real-time quantitative PXR reagents were from Applied Biosystems. The GenePORTER liposome transfection reagent was from Genlantis. PXR short hairpin RNA (shRNA) constructs were from Open Biosystems.
Immunohistochemistry. For PXR tissue immunostaining, paraffinembedded tissue sections or tissue arrays were deparaffinized, rehyrated, and antigen retrieved by placing in Declere 1Â working solution in an electric pressure cooker for 15 min. After a hot rinse with boiling Declere, slides were left to cool down for 5 min. After washing in deionized water, slides were processed for immunohistochemical staining using a Zymed Histostain-SP kit according to manufacturer's instructions. The sections of negative controls were stained after the same procedure except for the nonspecific rabbit IgG used as the primary antibody. Tissue sections were scored combining both the intensity and percentage of stained cells according to previous reports (22, 23) . Intensities were classified into 0 (no staining), 1 (weak staining), 2 (moderate staining), and 3 (strong staining). Ten percent of the groupings were used for the percentage of cells that stained positive. For each slide, a value-designated H score was derived from the formula, H score = (percentage of cells stained at intensity category 1 Â 1) + (percentage of cells stained at intensity category 2 Â 2) + (percentage of cells stained at intensity category 3 Â 3). Three areas were scored to obtain the average H score for each tumor section. This formula produces an H score in the range of 0 to 300, wherein 0 = none of the tumor cells stained and 300 = 100% of tumor cells stained strongly.
Immunocytochemistry. PC-3 cells were seeded into six-well plates containing cover glass. Next day, cells were fixed in 3% paraformaldehyde for 15 min, incubated with 0.1% Triton X-100 for 1 min, and blocked with 1% bovine serum albumin and 2% horse serum for 30 min. Then cells were incubated sequentially with purified rabbit PXR primary antibody (Biolegend) for 1 h (1:100 dilution), Alexa Fluor 488 goat anti-rabbit IgG (H + L) secondary antibody for 1 h (1:100 dilution). The slides were then washed, mounted in Prolong Gold antifade reagent with 4 ¶,6-diamidino-2-phenylindole and visualized with a BX41 system microscope (Olympus).
RT-PCR. The expression profile of PXR or its target genes, CYP3A4 and MDR1, was evaluated by semiquantitative RT-PCR. A normal human colon tissue sample (BioChain Institute, Inc.) and a human liver cancer cell line, HepG2, were used in parallel to compare the transcript levels of PXR in prostate cancer cells with human colon tissue and liver cancer cell line. Total RNA was extracted from cell cultures with TRIzol reagent. RT was done by Superscript III First-Strand synthesis system. Genes of interest were amplified by PCR from cDNA with the following primer pairs: PXR (348 bp), 5 ¶-TGTCATGACATGTGAAGGATG-3 ¶/5 ¶-TTGAAATGGGAGAAGGTAGTG-3 ¶; CYP3A4 (325 bp), 5 ¶-CTAGCACATCATTTGGACTG-3 ¶/5 ¶-ACAGAGC-TTTGTGGGACT-3 ¶; MDR1 (698 bp), 5 ¶-TCACCTTCGTCAGCTACTTCGG-3 ¶/5 ¶-CAGGAGGTCACAGCCGACTTTAAAC-3 ¶; b-actin (294 bp), 5 ¶-TCACCCA-CACTGTGCCCATCTACGA-3 ¶/5 ¶-CAGCGGAACCGCTCATTGCCAATGG -3 ¶. The PCR mixtures were initially denatured at 94jC for 2 min, followed by denaturation for 20 s at 94jC, primer-annealing for 30 s at 54.5jC, and extension for 1 min at 72jC for 45 cycles with the MJ Mini Personal Thermal Cycler (Bio-Rad Laboratories). A final extension for 5 min at 72jC ensured complete extension of the PCR products. The amplified DNA fragment sequences were determined directly with agarose gel electrophoresis. The b-actin was used for normalization.
Real-time PCR. RT-quantitative PCR for PXR target genes, CYP3A4, and MDR1 was done using an Applied Biosystems 7500 real-time PCR system (Applied Biosystems). The procedure of RNA isolation and RT was the same as above semiquantitative RT-PCR. Total RNA (300 ng) from each sample was used for cDNA synthesis. RNA quantity and quality of the different samples were determined by the 260:280 nm absorbance ratio using a BioSpec-mini DNA/RNA/protein analyzer (Shimadzu Corporation). Quantitative PCR was done using gene-specific primers:
The reference gene b-actin (5 ¶-TCACCCACACTGTGCCCATCTACGA-3 ¶/ 5 ¶-CAGCGGAACCGCTCATTGCCAATGG-3 ¶) was used for normalization. All reactions were done in a singleplex way. The total reaction volume was 20 AL containing 2Â SYBR Green PCR master mix, 100 nmol/L of each primer, and 2 AL cDNA as template. After two initial steps of 50jC for 2 min and 95jC for 10 min, the PCR reaction was run 40 cycles of 95jC for 15 s and 60jC for 1 min. Melt curve analyses were done for all samples and only sharp melting points were observed, indicating a specific signal and no primer dimers or mispriming. No template control was always included in each run to check for the presence of exogenous contaminant DNA. Standard curve was generated by serial dilution of cDNA. With the threshold cycle values in realtime PCR obtained, the amounts of CYP3A4 or MDR1 were then determined from standard curves. After normalization with the amount of b-actin, the expression levels in each time point were expressed as a ratio (%) compared with that of vehicle-treated cells (0 h, DMSO). Each sample was analyzed twice in triplicate, and data were analyzed using 7500 system SDS software (Applied Biosystems).
Cell culture and shRNA transfection. PC-3, DU145, and LNCap cells were grown in a RPMI 1640 containing 5% FBS, supplemented with antibiotics and antimycotics in a humidified incubator, with an atmosphere of 5% CO 2 , at 37jC. Cells were transfected with shRNA constructs at a 70% to 80% confluence using GenePORTER liposome transfection reagent. After the transfection, puromycin was added at final concentration of 5 Ag/mL to eliminate nontransfected cells and 1 Ag/mL to maintain transfected cells.
Chemotherapeutic sensitivity assay. PC-3 cells were tripsinized, resuspended, counted by Vi-cell XR cell viability analyzer (Beckman), and seeded into 96-well plates at an initial density of 10,000 cells per well. After attachment, cells were treated with Taxol or vinblastine for 72 h directly or after a 12-h or 48-h treatment of SR12813, a selective agonist of PXR (24) . Cell viability was measured by MTS assay. Plates were incubated at 37jC for 2 h, and the absorbance at 490 nm was measured in a plate reader (Thermo Electron).
Colony formation assay. The clonogenic efficiency of surviving fractions of tumor cells after exposure to drugs was determined by modified colony formation assay (25) . Basically, PC-3 cells were grown into 12-well plates at an initial density of 1,000 cells per well. After 12 h of pretreatment of SR12813 at different concentration (DMSO only, 0.2 and 1 Amol/L), the cells were then treated with vinblastine (1 Amol/L) or Taxol for 24 h. After treatment, the cells were then cultured in fresh RPMI media for 7 days. The colonies formed were then stained with Giemsa solutions and enumerated.
Luciferase assay. PC-3 cells were seeded into six-well plate. After attachment, cells were transiently transfected with LacZ and pGL-PXRE luciferase reporter constructs using GenePORTER liposome transfection reagents as described above. The pGL-PXRE was constructed by inserting two PXR-responsive fragments in the proximal (À362/+53) and distal (À7,836/À7,208) CYP3A4 promoters into pGL3 vector at XhoI and HindIII sites. Seventy-two hours later, cell lysates were harvested using cell culture lysis reagent, assayed for luciferase (Promega) and h-galactosidase activities (Invitrogen). The luciferase activity was normalized with h-galactosidase activity for transfection efficiency. All values were averaged from triplicate determinations in one individual experiment, and the experiment was repeated at least thrice.
Statistical analysis. Student's t test (two tails) was used to analyze the difference between two groups. For comparisons among three or more groups, ANOVA test was used. For statistical analysis of PXR immunoreactivities in prostate tumor specimens, nonparametric tests were used. Kruskal-Wallis test was used to test the difference in the ranks of scores of 3 or more independent groups. Dunnett's multiple comparison test was used to further compare the scores between two groups. The statistical tests were done using GraphPad Prism 4.00 for Windows (GraphPad Software). A P value, if smaller than 0.05, would reject the null hypothesis and accept the alternative hypothesis, i.e., the difference between groups is significant.
Results
Expression of PXR in prostate cancer. PXR expression has been reported in human endometrial and breast cancers (17, 18) . To examine whether PXR is expressed in prostate cancer, we first evaluated the expression of PXR at protein level in normal and cancerous human prostate tissues by immunohistochemistry. Tissue slides were stained with purified rabbit anti-PXR antibody (Biolegend). The human liver tissue, which has high-PXR expression, was used as a positive control (Fig. 1A) . As shown in Fig. 1 , PXR immunoreactivity was present in normal prostate tissue sample (Fig. 1A and C) , whereas no positive staining was observed in the negative control (Fig. 1A) . In normal prostate gland, PXR immunoreactivity was strong in the basal cells, whereas in normal differentiated epithelial cells, PXR staining was reduced (Fig. 1A  and C) . PXR immunoreactivities were detected in nearly all prostate adenocarcinoma examined (Fig. 1A and C) . Interestingly, nuclear localization of PXR immunoreactivities was noted in some tumors (Fig. 1A) . The PXR immunoreactivites in all tissues were scored and analyzed according to the tissue types and Gleason scores. As shown in Fig. 1B , in cancerous prostate tissues (n = 124), PXR immunoreactivities were significantly different from normal prostate tissues (n = 19), especially in those with Gleason score of 6 (n = 16). The H scores of prostate adenocarcinomas increased with Gleason scores until 6, but decreased when the Gleason score was >6.
Functional characterization of PXR expressed in prostate cancer cells. The detection of PXR expression in clinical specimens of prostate cancer led us to hypothesize a potential role of PXR in modulating tumor responses to chemotherapy via regulating the expression of DMEs. First, we determined the expression of PXR in established human prostate cancer cell lines. As shown in Fig. 2A , PXR expression at mRNA levels was detected in established prostate cancer LNCap, PC-3, and DU145 cells by RT-PCR. Immunocytochemical staining with a specific PXR antibody revealed that in PC-3 cells cultured in serum-containing media, PXR was mainly localized in the cytosol (Fig. 2B, left) . Treatment with SR12813, a selective and potent agonist of PXR (24), stimulated nuclear localization of PXR (Fig. 2B, right) , indicating that PXR expressed in PC-3 cells was responsive to ligand treatment.
Next, we examined the levels of CYP3A4 and MDR1 expression in PC-3 cells after treatment of SR12813. The levels of CYP3A4 and MDR1 expression in PC-3 cells after exposure to SR12813 were examined using quantitative PCR. As shown in Fig. 2C , exposure of PC-3 cells to SR12813 stimulated CYP3A4 expression at mRNA level up to 72 h, with peak stimulation (26.7-fold) recorded within 4 h of treatment. MDR1 expression at mRNA level was also stimulated by SR12813 treatment with peak stimulation around 28.1-fold at 8 h after treatment (Fig. 2C) . The data suggest that activation of PXR could stimulate the expression of DMEs in prostate cancer cells.
Increased resistance of PC-3 cells to chemotherapeutics after SR12813 treatment. To study whether above-described stimulation of DME expression as result of PXR activation can lead to changes in drug resistance, we examined the effects of SR12813 pretreatment on the resistance of PC-3 cells to Taxol and vinblastine, two chemotherapeutics widely used to treat a spectrum of malignancies including prostate cancer. It was found the preactivation of PXR by SR12813 led to an increased survival of PC-3 cells, as assessed by MTS viability assay, after treatment of Taxol (10 and 100 nmol/L; Fig. 3A) or vinblastine (0.3 and 0.6 Amol/L; Fig. 3B) . A similar increase in chemoresistance was observed for cells pretreated with SR12813 for 48 h (data not shown), consonant with the observations that SR12813 increased the gene expression of MDR1 and CYP3A4 at mRNA levels up to 72 h (Fig. 2C) .
The increased resistance of prostate cancer cells after preactivation of PXR with SR12813 was also confirmed by colony formation assay. As shown in Fig. 4, pretreatment with SR12813 , which increased the gene expression of CYP3A4 and MDR1 (Fig. 2C) , enhanced clonogenic survival of PC-3 cells after treatment of vinblastine (Fig. 4A) or Taxol (Fig. 4B) . The results further establish a potential role of PXR in resistance of prostate cancer cells toward Taxol and vinblastine.
Enhanced sensitivity toward chemotherapy in prostate cancer cells with reduced PXR activity. To further confirm the role of PXR in PC-3 resistance to chemotherapeutics, we knocked down the expression of PXR in PC-3 cells with the shRNA constructs. Total eight PXR shRNA constructs were used in this experiment. For the wild-type and PXR non-knockdown PC-3 cells, the PXR was detected as a band of 348 bp, whereas for the knockdown clones, PXR were undetected by RT-PCR (Fig. 5A) . The knockdown of PXR expression in P1622-1, P1622-3, and Pm1623-3 clones was further confirmed by reduced immunoreactivity of PXR (Fig. 5B) . In contrast, PC-3 and the P1620-4 clone retained intensive immunoreactivity of PXR with variable nuclear localization. The P1620-4 clone, in which PXR expression was not knocked down, was used as a control.
A luciferase reporter gene assay was used to evaluate the ability of PXR to stimulate CYP3A4 promoter activity. Wild-type PC-3, P1620-4 clone, or various clones with PXR expression knocked down were transiently transfected with a LacZ plasmid and a pGL-PXRE plasmid, which contains two PXR-responsive fragments in the CYP3A4 promoter, or a control vector. As shown in Fig. 5C , both the wild-type PC-3 and P1620-4 clone had strong PXR promoter activities when compared with the untransfected groups, indicating a basal expression of functional PXR in PC-3 cells. The promoter activities of PXR in all PXR knockdown cells were significantly lower than the wild-type or P1620-4 PC-3 cells (Fig. 5C) . 
SR12813 for 12 h followed by the 72-h treatment of Taxol (A) or vinblastine (B). *, P < 0.05, assayed by Student's t test, compared with the vehicle-treated group. Points, mean viability as a percentage of control (i.e., cells without chemotherapeutics treatment, 100%) from replicates (n = 9) from three separate experiments; bars , SE.
Finally, the PC-3 cells with PXR knocked down were subjected to chemotherapeutics. As shown in Fig. 5D , all three clones showed enhanced sensitivities to vinblastine or Taxol when compared with wild-type PC-3 cells. The results further suggest a role of PXR in determining the responses of prostate cancer cells toward chemotherapy.
Discussion
In the present study, the expression of PXR, a master regulator for DMEs, was detected in human prostate cancerous tissues and in established cancer cells. Treatment of PC-3 cells with SR12813, a selective agonist of PXR, stimulated the expression of MDR1 and CYP3A4 and enhanced the resistance of cancer cells toward chemotherapy. Down-regulation of PXR via shRNAs, on the other hand, sensitized cancer cells to Taxol and vinblastine treatment. Our data suggest an important role for PXR at local tumor region in determining the responses of prostate tumors to chemotherapy. It is the first time that a role of PXR in chemoresistance was shown in human prostate cancer cells.
The endogenous expression of PXR in both normal and cancerous prostate tissues raises an interesting question regarding the potential role of PXR in the normal function of prostate as well as in carcinogenesis. In normal prostate gland, the highest expression of PXR was detected in the basal layer, an area in which basal stem cells give rise to transit-amplifying cells that in turn undergo terminal differentiation in the luminal area. The pattern of PXR expression in the normal gland suggests an inverse relationship between PXR expression and epithelial differentiation. However, further studies are needed to address the possible inhibitory role of PXR in the terminal differentiation of prostate epithelial cells.
In cancerous tissues of prostate, PXR immunoreactivities were generally elevated when compared with normal tissues. When the PXR immunoreactivities in cancerous tissues were scored and analyzed as a function of tumor grade or Gleason score, tumors with Gleason score of 6 or grade II presented the highest levels of PXR expression. Interestingly, when tumors progress to a more advanced stage, the expression of PXR tends to be reduced. Another interesting observation is the nuclear translocation of PXR observed in some patients. Similar observations were also made in breast cancer cases (16) . Although not a precise indicator of activities in situ, the observed nuclear localization of PXR suggest that, at least in some tumors, PXR was activated, possibly due to the treatment patients received. Further studies are needed to determine how PXR is activated endogenously and whether PXR plays a physiologic role in the prostate.
A possible role of PXR in prostate biology and cancer progression is the regulation of cell death and survival pathways. A recent study using microarray analysis (26) identified >200 genes regulated by PXR, many of which concern intracellular metabolism, transport of essential small molecules, cell cycle, and survival mechanism. It remains to be studied, however, whether or not PXR activation has effects on the survival or proliferation of prostate cancer cells.
As a master regulator of many enzymes involved in drug metabolism, PXR may regulate the expression of DMEs in prostate cancer. In the past several decades, a myriad of targets have been identified in tumor resistance toward chemotherapy. MDR1 gene and its family members (27) and phase I and phase II metabolism enzymes (28) have been implicated in resistance of cancer cells toward chemotherapy. Our studies suggest that PXR is involved in drug resistance in PC-3 human prostate cancer cells. The upregulation of drug metabolism and excretion genes by PXR can reduce the clinical efficacy of antineoplastic agents, especially at low doses or when the in situ availability of the chemotherapeutics becomes a limiting factor as in the case of metronomic dosing or due to the poor vascularization of tumors. Whereas the doses of chemotherapeutics used in the present study are comparable with those in other in vitro studies (29, 30) , cautions should be exercised in extrapolation of the doses used in vitro to clinical settings. In the present studies, 10,000 tumor cells were used wherein chemotherapeutics had access to every single cell. However, in clinical settings, a gram of tumor mass may contain 10 9 tumor cells, and dependent on the status of vascularization, chemotherapeutics in the circulation may have limited access to some tumor cells. The amount of drugs available for each tumor cell may ultimately determine the efficacy of chemotherapy. Whereas it is plausible that the drug resistance mediated by PXR can be overcome by increasing the availability of drugs to tumors in situ through doseintense schedule of chemotherapeutics for the objective of attaining a cure in certain malignancies (e.g., breast cancer; ref. 31) or certain tissue-selective delivery to tumor tissues (32, 33) , an increase in PXR expression or activity in tumor cells may narrow the therapeutic window of chemotherapeutics due to the inherent side effects when delivered at high doses. The PXR-CYP and PXR-MDR1 pathways might be one of the main pathways for PXR to regulate drug resistance. Both drugs used in the study are the substrates of MDR1 and might be metabolized by the CYP family (34) (35) (36) (37) (38) (39) , and the MDR1 or CYP3A4 are highly regulated by PXR. Interestingly, Taxol has been identified as an activator of PXR (6, 21, 40) . Therefore, it may induce its own metabolism and excretion. Vincristine, an analogue of vinblastine, is a potential PXR ligand and induces ABCC2 and ABCC3 expression in carcinoma cells (20) . The expression of PXR in prostate cancer raises possibility that the intratumoral regulation of MDR1 and CYP3A4, or other DMEs, by PXR may lead to alterations in the efficacy of chemotherapeutics.
Due to the big space/volume and flexibility in ligand-binding domain (7, 41) , PXR can be activated by a variety of structurally diverse compounds. Known activators of PXR include many clinical drugs (42) , diet components (42), pesticide (7), bile acid, and other endogenous ligands (5) . Because most cancer patients use herbal supplements (43) , the potential activation of PXR by components of herb may alter the clinical efficacy of chemotherapeutics. More studies are clearly needed to address the potential interaction of drug-drug and drug-herb supplements in determining the clinical outcomes of chemotherapy in prostate cancer patients.
In summary, we detected PXR expression and distribution in normal and cancerous prostate tissues. PXR activation conferred upon prostate cancer cells with increased resistance toward chemotherapy, whereas down-regulation of PXR sensitized prostate cancer cells toward chemotherapy. If the activation of human PXR (hPXR) is one of the major underlying mechanisms of drug resistance in cancer chemotherapy, inhibition of PXR will be a new approach to enhance the clinical efficacy of prostate cancer chemotherapy. Recent identification of ketoconazole (15) and sulforaphane (44) as inhibitors of PXR activation raises an exciting possibility that these compounds can be used to intercede PXR The wild-type, PXR non-knockdown, or PXR knockdown PC-3 cells were transiently cotransfected with a LacZ plasmid and a control vector or a pGL-PXRE vector containing two PXR-responsive fragments in CYP3A4 promoter. After 72 h, cells were harvested and lyzed. The luciferase activity was measured and normalized for transfection efficiency with h-galactosidase activity. Calculated as the ratio of luciferase activity of transfectants to that of untransfected PC-3 cells. Columns, mean of assays done in triplicate; bars, SE. Represents one of three independent experiments. D, sensitivity of wild-type and PXR knockdown PC-3 cells to vinblastine (0.3 Amol/L) or Taxol (0.1 Amol/L). The wild-type PC-3, P1622-1, P1622-3, and Pm1623-3 were treated with chemotherapeutics for 72 h and then the cell viability was measured by MTS assay. *, P < 0.05; **, P < 0.01, when compared with the vehicle control (0.01% DMSO for Taxol; water for vinblastine).
